Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments

Fig. 2

Cumulative duration of follow-up in relation to the reported prevalence of the orphan conditions. Prevalence data derived from the relevant EMA Committee for Orphan Medicinal Products public summary of opinion for each treatment [3]. EMA, European Medicines Agency; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; OC, ovarian cancer; RCC, renal cell carcinoma; STS, soft tissue sarcoma

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172